Frankfurt
27.06.25 | 08:07
0,064 Euro
-0,62 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.06. | Isofol Medical AB: Isofol completes first cohort in ongoing clinical study with arfolitixorin | 92 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, June 12, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the first cohort in the ongoing phase Ib/II clinical study with... ► Artikel lesen | |
| 12.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.06.2025 | 178 | Xetra Newsboard | Das Instrument W1E JE00BSBJ5M88 ROSEBANK INDS LS -,001 EQUITY wird ex Kapitalmassnahme gehandelt am 12.06.2025 The instrument W1E JE00BSBJ5M88 ROSEBANK INDS LS -,001 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 11.06. | Isofol Medical AB: Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on 11 June 2025 | 75 | GlobeNewswire (Europe) | GOTHENBURG, 11 June 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its extra ordinary general meeting today at which the following main resolutions were passed by the shareholders.
The... ► Artikel lesen | |
| 05.06. | Isofol Medical AB: Isofol announces final terms of the rights issue and the potential overallotment issue | 50 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, 5 June 2025 - The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) ("Isofol" or the "Company") announced on 12 May 2025, that the Board of Directors, subject... ► Artikel lesen | |
| 21.05. | Isofol Medical AB: Isofol Medical AB (publ) publishes Interim report, January - March 2025 | 82 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 21, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January - March 2025 is now available on the company's... ► Artikel lesen | |
| 03.04. | Isofol (ST: ISOFOL) to receive financing to support Phase II & III trials of arfolitixorin in Japan | 292 | Edison Investment Research | Isofol Medical has announced that Solasia Pharma, its development and commercialisation partner in Japan, intends to invest c SEK140m to support planned Phase II and III trials of arfolitixorin in the... ► Artikel lesen | |
| 19.02. | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2024 | 71 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 19, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January - December 2024 is now available on the company's... ► Artikel lesen | |
| 12.11.24 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2024 | 188 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 12, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-September 2024 is now available, in Swedish... ► Artikel lesen | |
| 17.09.24 | Isofol Medical AB: Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin | 384 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 17, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary patentability report on a new international product... ► Artikel lesen | |
| 21.08.24 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-June 2024 | 244 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 21, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-June 2024 is now available, in Swedish, on the... ► Artikel lesen | |
| 30.07.24 | Isofol Medical AB: Isofol appoints Magdalena Hagman as new Chief Financial Officer | 275 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 30, 2024 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today that the company has appointed Margareta Hagman as the new Chief Financial Officer. She has extensive... ► Artikel lesen | |
| 16.07.24 | Isofol Medical AB: Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin | 381 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 16, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces results from two preclinical studies that support the dose-response relationship for arfolitixorin.... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,420 | -0,49 % | Valneva überträgt Impfstoffvertrieb in Deutschland an CSL | Valneva SE hat mit CSL Seqirus eine exklusive Vereinbarung über die Vermarktung und den Vertrieb seiner drei Impfstoffe in Deutschland geschlossen. Die Kooperation startet im Juli 2025 mit dem Chikungunya-Impfstoff... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
| CARDIOL THERAPEUTICS | 1,304 | +8,49 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -0,67 % | Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock | ||
| CENTOGENE | 0,149 | +49,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,880 | +0,24 % | Atai Beckley: Big Deal | Fast genau vier Jahre nach dem Börsenstart am 18. Juni 2021 gibt es signifikante Veränderungen bei Atai Life Science: So schließt sich das auf die Behandlung psychischer Erkrankungen spezialisierte... ► Artikel lesen | |
| BIOMERIEUX | 119,80 | +0,50 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| CYCLACEL | 0,290 | -100,00 % | Cyclacel Pharmaceuticals, Inc.: Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement | KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company that develops innovative... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,925 | -5,13 % | XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer | Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL") announced... ► Artikel lesen | |
| GENUS | 22,800 | +1,79 % | Dividendenbekanntmachungen (04.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERICAN EXPRESS COMPANY US0258161092 0,82 USD 0,742 EUR BARCLAYS PLC GB0031348658 0,055 GBP EUR BRISTOL-MYERS SQUIBB COMPANY US1101221083 0... ► Artikel lesen | |
| ABIONYX PHARMA | 1,164 | +0,34 % | ABIONYX Pharma Announces Approval of All Resolutions Put to the Vote at Its Combined General Meeting | Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's... ► Artikel lesen | |
| ANAPTYSBIO | 20,000 | +4,17 % | AnaptysBio, Inc.: Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA | Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month? blinded treatment periodFavorable safety and tolerability, particularly... ► Artikel lesen | |
| MEIRAGTX | 5,600 | +1,82 % | MeiraGTx erhält britische Genehmigungen für Hologen-Transaktion |
ISOFOL MEDICAL AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,62 % bei einem Aktienkurs von 0,064 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISOFOL MEDICAL AB finden Sie auf Wallstreet Online.